Clinical trials: Advanced NET of GI Origin
Advanced NET of GI Origin, Advanced NET of Lung Origin
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of…
- Conditions
- Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
- Trial name
- RADIANT-4 (NCT01524783)
- Testing
- Everolimus, Best suportive care (BSC)
- Where
- 97 sites in United States, Austria and 23 more
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
This study aimed to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or…
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02955069
- Testing
- PDR001
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine (NE) Tumors, Advanced NET of GI Origin
AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
A phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours.
- Trial name
- BHARAT-3 (NCT07640737)
- Testing
- AUR103 Calcium
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aurigene Discovery Technologies Limited